Peter Attia MD273 ‒ Prostate health: common problems, cancer prevention, screening, treatment, and more
CHAPTERS
- 0:00 – 6:21
What the Prostate Does and How Urinary Symptoms Develop With Age
Peter Attia and Ted Schaeffer begin with the prostate's role as an exocrine gland in the reproductive system. They then cover how age-related enlargement narrows the urethra and affects the bladder, causing lower urinary tract symptoms in a large share of older men.
- •The prostate develops in utero under fetal androgens and makes roughly 50-60% of semen
- •Its position along the urethra means problems affect both reproduction and urination
- •About 50-60% of men at age 50 and 75-80% at age 60 have lower urinary tract symptoms
- •Symptoms include weak stream, hesitation, urgency and frequency
- •Urethral compression and a stiffer, thickened bladder both contribute
- 6:21 – 15:10
Behavioral Fixes for Nighttime Urination and Urinary Symptoms
Schaeffer describes first-line behavioral steps for urinary symptoms: managing fluid timing and type, caffeine and alcohol, and voiding diaries. They discuss why nocturia becomes more common with age, including declining antidiuretic hormone, capillary leak and edema, and sleep apnea.
- •Fluid timing, caffeine and alcohol (which blunts antidiuretic hormone) all affect nighttime urination
- •A diary of intake and voiding often shows excessive fluid intake
- •The nighttime surge of antidiuretic hormone weakens with each decade of age
- •Peripheral edema can act like a nighttime IV drip, and knee-high TED stockings can help
- •Sleep apnea drives nocturnal urine production, giving another reason to get it diagnosed and treated
- 15:10 – 27:18
Medications: Desmopressin, Alpha Blockers, 5-Alpha Reductase Inhibitors and M3 Agonists
The conversation moves through drug options for urinary symptoms. Alpha blockers are the frontline choice, with newer ones sparing ejaculation. 5-alpha reductase inhibitors are reserved for large prostates and lower PSA, and antimuscarinics carry cognitive risks that M3 agonists avoid.
- •Low-dose desmopressin is raised as a tool for nighttime urination with no clear cause
- •Alpha blockers relax prostate smooth muscle; alfuzosin and silodosin are the newer third-generation options
- •Finasteride and dutasteride shrink large prostates (over about 70 g) by 20-30% but take six or more months and cut PSA roughly in half
- •Antimuscarinics are linked to worsening dementia and cognitive problems in older people
- •Men's long urethra makes obstructive symptoms far more common than in women, so alpha blockers come first
- 27:18 – 41:38
Surgical Options: TURP, Minimally Invasive Procedures and HoLEP
Schaeffer and Attia compare surgical treatments for an enlarged prostate. They cover bipolar TURP, UroLift and Rezum, and open simple prostatectomy, then HoLEP, which they explain through an orange analogy and credit to his partner Amy Krambeck.
- •TURP scrapes tissue out piecemeal, and modern bipolar versions use saline to avoid post-TUR hyponatremia
- •Less invasive options (UroLift, Rezum) are less durable, and Schaeffer says he never recommends UroLift
- •HoLEP removes the whole inner adenoma along its natural plane, so there is less bleeding and often no catheter
- •Large prostates were once removed by open simple prostatectomy, now done robotically or by HoLEP
- •Normal prostate is a golf ball, 100 g an orange, and 400 g a large grapefruit
- 41:38 – 49:09
Prostate Size, Cancer Risk and Small Prostates With Persistent Symptoms
Attia asks whether very large prostates run in families and how size relates to cancer. Schaeffer says size is inversely related to aggressive cancer risk and tied to the testosterone-to-estrogen ratio. He adds that a small prostate with stubborn symptoms calls for a workup for other causes such as urothelial carcinoma, and he describes what top HoLEP surgeons can achieve.
- •Very large prostates tend to run in families
- •Bigger prostates are inversely correlated with aggressive cancer, possibly through the T-to-E ratio
- •Schaeffer believes prostate cancer risk is largely set in the 30s and 40s
- •A small prostate with unresponsive symptoms warrants urinary cytology to rule out urothelial carcinoma
- •A 95-year-old with a 450 g prostate went home after a HoLEP that other hospitals declined
- 49:09 – 1:09:32
Prostatitis and Chronic Pelvic Pain: Diagnosis and Treatment
Attia recounts his own brush with prostatic discomfort, and Schaeffer explains that chronic pelvic pain syndrome is a catch-all with many causes. They walk through the Stamey four-glass test and treatments including pelvic floor myofascial release, NSAIDs and, in a clinical trial, mast cell inhibitors.
- •The cause is often unknown, but infection, inflammation and pelvic floor dysfunction are all possible
- •Constipation and travel can affect the prostate because of its close anatomical ties to the rectum
- •The Stamey test captures urine in four phases to localize infection, using a lower bacterial threshold for the prostate
- •Transrectal myofascial release can be a game changer for tight pelvic floor muscles
- •Schaeffer prefers naproxen over repeated antibiotic courses, and his father's trial targets mast cell dysfunction
- 1:09:32 – 1:15:00
Urosepsis Risk in Alzheimer's Patients and Catheter Care
Attia notes that Alzheimer's patients often die of complications such as urosepsis. Schaeffer describes what caregivers can do, including good hygiene, avoiding indwelling catheters, using intermittent catheterization, and keeping the person hydrated.
- •Dementia patients may not notice or report infection symptoms, so a urinary tract infection can turn into sepsis within days
- •Intermittent catheterization poses less infection risk than constant catheterization because of dwell time
- •Bacteria can climb a catheter and reach the bladder within about 48 hours
- •Dehydration concentrates urine and worsens the effect of any bacteria
- •Catheters left in place should be changed every three to four weeks, and walking and reminders to drink help
- 1:15:00 – 1:33:33
Prostate Cancer Overview, Androgen Biology and Post-Finasteride Syndrome
The discussion pivots to prostate cancer, its favorable ratio of deaths to diagnoses, and how androgens and androgen receptors work, including DHT's role. They then turn to post-finasteride syndrome, its sexual and mood symptoms, its estimated frequency, and how finasteride masks rising PSA.
- •About 250-260,000 new diagnoses against about 34,000 deaths, a much better ratio than pancreatic cancer
- •The androgen receptor is a transcription factor that DHT activates about ten times more potently than testosterone
- •5-alpha reductase converts testosterone to DHT mainly in the prostate and hair follicles
- •Schaeffer estimates roughly one in ten men may have appreciable post-finasteride symptoms, sometimes permanent
- •Finasteride lowers PSA by about half within a few years, and a rising PSA on it is a warning sign
- 1:33:33 – 1:46:10
Testosterone, DHT and Cancer Biology: Luminal vs. Basal Tumors
Attia asks how testosterone and DHT relate to cancer risk across a man's life, and Schaeffer points to epigenetic resetting. He then describes his analysis of 100,000 tumor transcriptomes, which separates androgen-sensitive luminal tumors from more lethal basal-like tumors.
- •Young men have peak androgens yet rarely get prostate cancer, so timing and epigenetic changes matter
- •Luminal tumors are androgen-sensitive and rarely become metastatic
- •Basal-like tumors can survive without testosterone and are more capable of spreading
- •This is why Schaeffer is comfortable with testosterone supplementation in some men with low T
- •Decipher genomic scores are becoming an entry criterion for prostate cancer clinical trials
- 1:46:10 – 2:07:16
Where Prostate Cancer Arises and Its Genetic and Non-Genetic Risk Factors
Schaeffer explains that most cancers arise in the peripheral zone and how this affects PSA monitoring. He then covers germline genes such as BRCA2, SNP-based risk scores, ancestry, family history, smoking, metabolic disease and the ejaculation-frequency study.
- •Most tumors begin in the peripheral zone, near the nerves and sphincter
- •Less than about 2% of localized cases are attributed to germline mutations; BRCA2 carriers need intensive screening, not prophylactic prostatectomy
- •A high SNP-based genomic risk score carries about a five-fold risk, similar to BRCA2 deficiency
- •The higher risk in Black men appears more environmental than hardwired, according to Schaeffer
- •Family history (father, brother or uncle), smoking and metabolic disease raise risk or aggressiveness, and the youngest patient he treated was 34
- 2:07:16 – 2:25:58
PSA Screening: Free PSA, Density, Velocity and Guidelines
Schaeffer explains what PSA is and how free PSA, PSA density and advanced tests refine interpretation. He and Attia then debate screening frequency, with Attia pushing for annual testing and Schaeffer describing the NCCN approach and the value of a baseline PSA.
- •PSA liquefies semen and leaks into blood; a high free-PSA percentage suggests benign tissue
- •PSA density of about 0.1 or less is reassuring, while higher values call for more testing
- •Advanced tests such as PHI and the 4K score add information, and elevated PSA should be rechecked first
- •The NCCN suggests a baseline PSA at 45 with follow-up intervals based on the result
- •Attia argues that PSA, free PSA and density cheaply identify risk and that patients should take ownership of monitoring
- 2:25:58 – 2:40:45
MRI-Guided Evaluation and Transrectal vs. Transperineal Biopsy
The two argue that PSA screening, done well, avoids unnecessary biopsies, and Schaeffer says an MRI should come before any biopsy. They cover PI-RADS scoring and how targeted biopsies are done, then compare transrectal and transperineal approaches, including his 16-institution randomized trial of infection rates.
- •Abnormal advanced PSA testing followed by MRI cut biopsies by 50% and improved detection of significant disease in a randomized trial
- •A 3T multiparametric MRI yields a PI-RADS score from 1 to 5, and scores 3-5 usually prompt biopsy
- •Transrectal biopsy carries about a 1-4% infection risk, while transperineal can be done without antibiotics
- •Schaeffer says infection rates with transperineal approach are under 1 in 1,000
- •His trial's other endpoints are pain, side effects and cancer detection
- 2:40:45 – 3:03:00
Biopsy Results, Gleason Scores and Active Surveillance for Gleason 6
Schaeffer explains who needs a biopsy and how the Gleason pattern and sum are derived. They discuss why Gleason 6 disease is usually monitored rather than treated, supported by Hopkins surveillance data and the improved accuracy of MRI-targeted biopsies.
- •Biopsy decisions weigh PI-RADS score, PSA density and percent free PSA, and a risk calculator from his colleague Ashley Ross is mentioned
- •A standard biopsy takes 12 systematic cores plus about three from any target
- •Gleason 3+3 tumors showed no lymph node metastases in surgical series, so low-volume Gleason 6 can be watched
- •Surveillance involves PSA every six months, MRI and a confirmatory biopsy at one year
- •In the Hopkins cohort, about 12.5% had a grade change in five years and about 0.1% progressed to incurable disease
- 3:03:00 – 3:18:44
Gleason 7 and Higher: Staging, Metastasis and Radiation Advances
Schaeffer explains why the percentage and millimeters of pattern 4 matter in Gleason 7, and how Gleason 8 and above are managed. They cover PSMA PET staging, where prostate cancer spreads, staging and curability of node-positive disease, and radiation options including hydrogel spacers and MRI-guided delivery.
- •Gleason 7 ranges from small amounts of pattern 4, which may be monitored, to more than 50% pattern 4, which is treated like 8-9
- •Higher-grade disease needs a PSMA PET scan to stage it
- •The most common metastatic sites are lymph nodes, then bone; spread to lung and other sites occurs
- •Pelvic lymph node disease is stage IV but can still be curable, and radiation is probably the best local control
- •SPACE-OAR hydrogel and MRI-guided radiation sharply reduce rectal side effects
- 3:18:44 – 3:46:39
Systemic Therapy for Prostate Cancer and the Shift to Robotic Prostatectomy
Schaeffer explains how androgen deprivation therapy is used with radiation and for metastatic disease. He describes newer agents such as abiraterone and the 'amide' drugs, with their survival benefits and toxicities. The conversation then turns to prostatectomy, now done almost entirely robotically.
- •ADT sensitizes tumors to radiation, and oral LHRH antagonists allow faster testosterone recovery than depot agonists
- •Median survival with metastatic disease is about two to three years untreated and about four years on ADT alone
- •Adding abiraterone or enzalutamide, apalutamide or darolutamide extends life by about two years, with median survivals of seven to eight years
- •Toxicities include seizures and sleepiness with some agents and blood pressure effects with abiraterone
- •Schaeffer last did an open prostatectomy in 2016, and robotic surgery is now standard
